title: Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients.
abstract: It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8+ T cells) appeared to perform better for this purpose.
authors: Microbiology Service, Hospital Clínico Universitario, Fundación INCLIVA, Valencia, Spain.
authors: Estela
authors: E
authors: Giménez
authors: Hematology and Medical Oncology Service, Hospital Clínico Universitario, Fundación INCLIVA, Valencia, Spain Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
authors: Carlos
authors: C
authors: Solano
authors: Clinic Pharmacology Service, Clínica Universidad de Navarra, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain.
authors: José Ramón
authors: JR
authors: Azanza
authors: Hematology and Medical Oncology Service, Hospital Clínico Universitario, Fundación INCLIVA, Valencia, Spain.
authors: Paula
authors: P
authors: Amat
authors: Microbiology Service, Hospital Clínico Universitario, Fundación INCLIVA, Valencia, Spain Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain david.navarro@uv.es.
authors: David
authors: D
authors: Navarro
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000601:surgery; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003587:Cytomegalovirus / Q000187:drug effects / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D004279:DNA, Viral / Q000097:blood; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use*; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D015470:Leukemia, Myeloid, Acute / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery; D010750:Phosphoproteins / Q000097:blood; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000601:surgery; D033581:Stem Cell Transplantation; D066027:Transplant Recipients; D000077562:Valganciclovir; D014763:Viral Matrix Proteins / Q000097:blood
chemical_list: D004279:DNA, Viral; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C464963:pp67 protein, human cytomegalovirus; D007371:Interferon-gamma; D000077562:Valganciclovir; D015774:Ganciclovir